RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.

David E.I. Pyott

A collection of news and information related to David E.I. Pyott published by this site and its partners.

Top David E.I. Pyott Articles see all

Displaying items 1-5
  • Allergan sale to Actavis complete; CEO David Pyott is leaving

    Allergan sale to Actavis complete; CEO David Pyott is leaving
    The $70-billion purchase of Botox maker Allergan Inc. of Irvine by Irish company Actavis has closed, Actavis confirmed Tuesday.
  • Office Depot CEO could walk with $39 million after merger

    Office Depot CEO could walk with $39 million after merger
    After less than two years on the job, Office Depot CEO Roland Smith could receive $39 million if the Staples-Office Depot merger is finalized, executive pay experts say. Smith, 60, would leave with a $7 million severance, roughly twice his salary and...

    Few Allergan execs to keep top jobs in Actavis takeover

    Few Allergan execs to keep top jobs in Actavis takeover
    The soon-to-be owner of Irvine-based Allergan Inc. announced sweeping leadership changes that pass over many current executives including the Botox maker's CEO. Irish pharmaceutical giant Actavis expects to finalize its $66-billion acquisition in the...

    Allergan sale to Actavis thwarts takeover attempt by Valeant

    Allergan sale to Actavis thwarts takeover attempt by Valeant
    Botox maker Allergan Inc., an Irvine company that started as a purveyor of eye drops and grew into one of the most respected pharmaceutical companies in the country, agreed to be acquired by Irish firm Actavis for $66 billion. The deal thwarts a...

    Valeant says it's willing to raise offer for Allergan to $200 a share

    Valeant says it's willing to raise offer for Allergan to $200 a share
    As shareholders of Botox maker Allergan Inc. prepare for a vote on the company's future, a Canadian suitor said it's willing to increase its offer to buy the Irvine firm. J. Michael Pearson, chief executive of Valeant Pharmaceuticals International Inc.,...